CA2015294A1 - Generation et expansion de cellules lak - Google Patents

Generation et expansion de cellules lak

Info

Publication number: CA2015294A1
Authority: CA; Canada
Prior art keywords: cells; lak; cell; culture; days
Prior art date: 1989-04-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002015294A

Other languages

English (en)

Inventor

John J. Rinehart

Joseph D. Irr

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Terumo Corp

EIDP Inc

Ohio State University Research Foundation

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-28

Filing date

1990-04-24

Publication date

1990-10-28

1990-04-24 Application filed by Individual filed Critical Individual

1990-10-28 Publication of CA2015294A1 publication Critical patent/CA2015294A1/fr

Status Abandoned legal-status Critical Current

Links

210000004027 cell Anatomy 0.000 claims abstract description 95
210000003810 lymphokine-activated killer cell Anatomy 0.000 claims abstract description 41
238000000034 method Methods 0.000 claims abstract description 24
108010002350 Interleukin-2 Proteins 0.000 claims abstract description 23
210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 23
210000002966 serum Anatomy 0.000 claims abstract description 22
230000000694 effects Effects 0.000 claims abstract description 18
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 9
238000012258 culturing Methods 0.000 claims abstract description 9
210000001616 monocyte Anatomy 0.000 claims abstract description 9
239000001301 oxygen Substances 0.000 claims abstract description 9
229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
210000005105 peripheral blood lymphocyte Anatomy 0.000 claims abstract description 9
150000008575 L-amino acids Chemical class 0.000 claims abstract description 4
VSDUZFOSJDMAFZ-VIFPVBQESA-N methyl L-phenylalaninate Chemical compound COC(=O)[C@@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-VIFPVBQESA-N 0.000 claims abstract description 4
239000012737 fresh medium Substances 0.000 claims description 12
239000002609 medium Substances 0.000 claims description 11
230000010261 cell growth Effects 0.000 claims description 9
229920001577 copolymer Polymers 0.000 claims description 8
239000001963 growth medium Substances 0.000 claims description 7
239000000463 material Substances 0.000 claims description 7
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 6
239000005977 Ethylene Substances 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 6
210000005259 peripheral blood Anatomy 0.000 claims description 6
239000011886 peripheral blood Substances 0.000 claims description 6
230000003013 cytotoxicity Effects 0.000 claims description 4
231100000135 cytotoxicity Toxicity 0.000 claims description 4
229920001971 elastomer Polymers 0.000 claims description 4
239000000806 elastomer Substances 0.000 claims description 4
229920000554 ionomer Polymers 0.000 claims description 4
230000002101 lytic effect Effects 0.000 claims description 4
235000004279 alanine Nutrition 0.000 claims description 3
125000005907 alkyl ester group Chemical group 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
235000003704 aspartic acid Nutrition 0.000 claims description 2
238000003556 assay Methods 0.000 claims description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
235000018417 cysteine Nutrition 0.000 claims description 2
235000013922 glutamic acid Nutrition 0.000 claims description 2
239000004220 glutamic acid Substances 0.000 claims description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
235000004554 glutamine Nutrition 0.000 claims description 2
229920000092 linear low density polyethylene Polymers 0.000 claims description 2
239000004707 linear low-density polyethylene Substances 0.000 claims description 2
230000035699 permeability Effects 0.000 claims description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
235000008729 phenylalanine Nutrition 0.000 claims description 2
229920000728 polyester Polymers 0.000 claims description 2
235000013930 proline Nutrition 0.000 claims description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
235000002374 tyrosine Nutrition 0.000 claims description 2
239000004474 valine Substances 0.000 claims description 2
239000004711 α-olefin Substances 0.000 claims description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
150000002148 esters Chemical class 0.000 abstract description 6
102000000588 Interleukin-2 Human genes 0.000 description 19
150000002500 ions Chemical class 0.000 description 11
239000012636 effector Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
239000012980 RPMI-1640 medium Substances 0.000 description 6
239000006285 cell suspension Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000006698 induction Effects 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000004913 activation Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000002659 cell therapy Methods 0.000 description 3
230000036512 infertility Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
239000003855 balanced salt solution Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000000743 Interleukin-5 Human genes 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
208000037844 advanced solid tumor Diseases 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000011393 cytotoxic chemotherapy Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000012953 feeding on blood of other organism Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
KWKAKUADMBZCLK-UHFFFAOYSA-N methyl heptene Natural products CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
238000002616 plasmapheresis Methods 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000009987 spinning Methods 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000002476 tumorcidal effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Hematology (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Superconductors And Manufacturing Methods Therefor (AREA)
Sampling And Sample Adjustment (AREA)
Inert Electrodes (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

CA002015294A 1989-04-28 1990-04-24 Generation et expansion de cellules lak Abandoned CA2015294A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34515989A	1989-04-28	1989-04-28
US345,159		1989-04-28

Publications (1)

Publication Number	Publication Date
CA2015294A1 true CA2015294A1 (fr)	1990-10-28

Family

ID=23353798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002015294A Abandoned CA2015294A1 (fr)	1989-04-28	1990-04-24	Generation et expansion de cellules lak

Country Status (6)

Country	Link
EP (1)	EP0475961A1 (fr)
JP (1)	JPH05505093A (fr)
AU (1)	AU5552390A (fr)
CA (1)	CA2015294A1 (fr)
HU (1)	HU904376D0 (fr)
WO (1)	WO1990013628A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04299983A (ja) *	1991-01-31	1992-10-23	Terumo Corp	付着リンホカイン活性化キラー細胞の産生・増加方法
DE4244437A1 (de) *	1992-12-29	1994-07-28	Horst Dr Med Kief	Verfahren zur Gewinnung körpereigener Zytokine
JP4308350B2 (ja) *	1998-11-27	2009-08-05	小林製薬株式会社	シイタケ菌糸体抽出物を含有するｌａｋ活性スクリーニング物質およびそれを用いたｌａｋ活性スクリーニング法
WO2003044183A1 (fr) *	2001-11-22	2003-05-30	Medigenes	Cellules tueuses a lymphokine activee transferee du gene interleukine 2
CN101120083B (zh)	2003-10-08	2013-03-27	威尔森沃尔夫制造公司	利用透气性材料进行细胞培养的方法及装置
US7745209B2 (en)	2005-07-26	2010-06-29	Corning Incorporated	Multilayered cell culture apparatus
CN101611133A (zh)	2006-12-07	2009-12-23	威尔森沃尔夫制造公司	高效装置及培养细胞的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2529321B2 (ja) *	1986-04-28	1996-08-28	エンドトロニックスインコーポレーテッド	白血球を培養する方法
CA1300058C (fr) *	1987-01-29	1992-05-05	Joseph D. Irr	Procede de preparation de lymphocytes k actives

1990
- 1990-04-24 CA CA002015294A patent/CA2015294A1/fr not_active Abandoned
- 1990-04-30 JP JP2507110A patent/JPH05505093A/ja active Pending
- 1990-04-30 AU AU55523/90A patent/AU5552390A/en not_active Abandoned
- 1990-04-30 EP EP90907837A patent/EP0475961A1/fr not_active Withdrawn
- 1990-04-30 WO PCT/US1990/002250 patent/WO1990013628A1/fr not_active Ceased
- 1990-04-30 HU HU904376A patent/HU904376D0/hu unknown

Also Published As

Publication number	Publication date
HU904376D0 (en)	1992-01-28
EP0475961A1 (fr)	1992-03-25
JPH05505093A (ja)	1993-08-05
AU5552390A (en)	1990-11-29
WO1990013628A1 (fr)	1990-11-15

Legal Events

Date	Code	Title	Description
1992-10-26	FZDE	Discontinued

Publication	Publication Date	Title
US11827903B2 (en)	2023-11-28	Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
Nikiforow et al.	2003	Cytolytic CD4+-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation
JP2529321B2 (ja)	1996-08-28	白血球を培養する方法
JP6081483B2 (ja)	2017-02-15	Ｔ細胞を増殖させるプロセス
RU2348418C2 (ru)	2009-03-10	Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей
Pullarkat et al.	2002	Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells
US5374549A (en)	1994-12-20	Process of enriching adherent CD4+ T cells from monocyte depleted peripheral blood mononuclear cells with interleukin 2 and interleukin 4
CN114085812A (zh)	2022-02-25	一种高表达cd106和/或cd142表达降低的间充质干细胞群、其制备方法及应用
JP7802941B2 (ja)	2026-01-20	ガンマデルタｔ細胞の増殖培養方法
Hudson et al.	1984	Trypanosoma cruzi: continuous cultivation with murine cell lines
AU5552390A (en)	1990-11-29	Generation and expansion of lak cells
Dock et al.	1980	Peripheral blood monocytes in the autologous mixed lymphocyte reaction
Whiteside et al.	1988	In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors
Haraguchi et al.	1992	Suppression of human interferon-γ production by a 17 amino acid peptide homologous to the transmembrane envelope protein of retroviruses: evidence for a primary role played by monocytes
US5198334A (en)	1993-03-30	Protection of natural killer cell cytolytic activity in peripheral blood mononuclear cells
Snider et al.	1986	IN VITOR AND IN VIVO CYTOTOXICITY OF T CELLS CLONED FROM REJECTING ALLOGRAFTS
CA2064072A1 (fr)	1991-01-22	Preparation de cellules lak adherentes humaines
CA2060278A1 (fr)	1992-08-01	Production amelioree de lymphocytes adherents, actives par la lymphokine, au moyen d'interleukine-2 et d'interleukine-4, a partir de lymphocytes circulants humains, traites par l'ester methylique de l-phenylalanine
Winters et al.	1974	New cell line derived from a human chondrosarcoma
Togami et al.	1991	Studies of serum-free medium for the generation of lymphokine-activated killer cells
KR20010046514A (ko)	2001-06-15	인간의 대식세포로부터 수상돌기 세포 추출 및 분화 유도
JPWO2006011681A1 (ja)	2008-05-01	白血球培養用血液の保存方法、輸送方法、末梢血単核球の保存方法、輸送方法及びそれらを用いた白血球の培養方法
MXPA96003788A (en)	1998-09-18	Cultivation and extracorporal cellular transplantation equipment containing linking f
HK1086597B (en)	2009-09-18	Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines